Cart
sales@molnova.com
Omburtamab
CAS No. 1895083-75-6
Omburtamab( —— )
Catalog No. M37163 CAS No. 1895083-75-6
Omburtamab is a monoclonal antibody targeting CD276, often conjugated to 131 radioactive iodine ions, used for radioimmuno positron emission tomography studies.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 491 | In Stock |
|
| 10MG | 734 | In Stock |
|
| 25MG | 1102 | In Stock |
|
| 50MG | 1451 | In Stock |
|
| 100MG | 1944 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameOmburtamab
-
NoteResearch use only, not for human use.
-
Brief DescriptionOmburtamab is a monoclonal antibody targeting CD276, often conjugated to 131 radioactive iodine ions, used for radioimmuno positron emission tomography studies.
-
DescriptionOmburtamab is an anti-CD276 (also known as B7-H3) monoclonal antibody, CD276 is a B7/CD28 immunoglobulin superfamily member expressed among solid human tumours. Omburtamab can bind tumor tissues and be used in various cancers research.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorImmunology/Inflammation related
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1895083-75-6
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Liu J, et al. Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes. J Hematol Oncol. 2021 Jan 29;14(1):21.?
molnova catalog
related products
-
[Tyr0]-BNP-32 (human...
[Tyr0]-BNP-32 (human)
-
Brain Injury Derived...
Brain Injury Derived Neurotrophic Peptide
-
HBVpol502, HBV polym...
HBVpol502, HBV polymerase (502 - 510)
